Key Details
Price
$55.50Annual Revenue
$486.82 MAnnual EPS
$0.85Annual ROE
4.72%Beta
0.79Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 08, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 18, 2013Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Here is how ANI Pharmaceuticals (ANIP) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants David Amsellem - Piper Sandler Gary Nachman - Raymond James Vamil Divan - Guggenheim Securities Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals Inc Third Quarter 2024 Earnings Results Call. Please note that this call is being recorded.
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago.
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows:
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FAQ
- What is the primary business of ANI Pharmaceuticals?
- What is the ticker symbol for ANI Pharmaceuticals?
- Does ANI Pharmaceuticals pay dividends?
- What sector is ANI Pharmaceuticals in?
- What industry is ANI Pharmaceuticals in?
- What country is ANI Pharmaceuticals based in?
- When did ANI Pharmaceuticals go public?
- Is ANI Pharmaceuticals in the S&P 500?
- Is ANI Pharmaceuticals in the NASDAQ 100?
- Is ANI Pharmaceuticals in the Dow Jones?
- When was ANI Pharmaceuticals's last earnings report?
- When does ANI Pharmaceuticals report earnings?
- Should I buy ANI Pharmaceuticals stock now?